Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • Bitcoin USD

    62,692.77
    +2,889.06 (+4.83%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • Dow

    38,675.68
    +450.02 (+1.18%)
     

  • Nasdaq

    16,156.33
    +315.37 (+1.99%)
     

  • Gold

    2,310.10
    +0.50 (+0.02%)
     

  • Crude Oil

    77.99
    -0.96 (-1.22%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Equity Research
·2-min read

For the quarter ended March 2024, Danaher (DHR) reported revenue of $5.8 billion, down 19.1% over the same period last year. EPS came in at $1.92, compared to $2.36 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $5.64 billion, representing a surprise of +2.85%. The company delivered an EPS surprise of +11.63%, with the consensus EPS estimate being $1.72.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total Growth - Organic sales (Core): -4% versus -6.9% estimated by four analysts on average.

  • Total sales- Diagnostics: $2.53 billion versus the four-analyst average estimate of $2.43 billion. The reported number represents a year-over-year change of +6.4%.

  • Total sales- Life Sciences: $1.75 billion versus $1.72 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.

  • Total sales- Biotechnology: $1.52 billion versus the four-analyst average estimate of $1.49 billion.

  • Operating profit- Life Sciences: $235 million versus $288.47 million estimated by three analysts on average.

  • Operating profit- Biotechnology: $325 million versus $350.46 million estimated by three analysts on average.

  • Operating profit- Other: -$78 million versus -$71.44 million estimated by three analysts on average.

  • Operating profit- Diagnostics: $830 million compared to the $651.02 million average estimate based on three analysts.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned -4.7% over the past month versus the Zacks S&P 500 composite's -4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Danaher Corporation (DHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research